Zeltia Group Fails to Win U.K. Backing for Ovarian Cancer Drug

Bloomberg -- Zeltia SA (ZEL)’s Yondelis failed to win the recommendation of the U.K.’s health-cost agency as a treatment for ovarian cancer, even after the company offered to limit the expense of the medicine.